Contents hide 1 Multiple Myeloma 1.1 Starting doses 1.2 Dose reductions 1.2.1 For starting dose of 4 mg Ixazomib is an oral proteasome inhibitor used in the treatment of multiple myeloma. Ixazomib is the first oral second-generation proteasome inhibitor that was approved by the FDA. Multiple Myeloma Indicated in patients who have received at least 1 prior therapy Use in combination with lenalidomide and dexamethasone Continue treatment until disease progression or unacceptable toxicity Starting doses Ixazomib: 4 mg PO on days 1, 8, and 15 of a 28-day cycle; take 1 hr ac or 2 hr pc Lenalidomide: 25 mg PO … Continue reading Generic (Ixazomib) ISADX